Outsourcing

Articles

A UC Berkeley survey provides insight into biopharma's risk concerns and strategies.

Survey: Optimizing Global Biopharmaceutical Operations Through Risk Mitigation and Management

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends.

The Future of BioPharma

Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.

Key talks from the recent PDA/FDA regulatory conference highlight room for improvement.

Advice for Enhancing the Client–Sponsor Relationship

Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.

Gauging Biopharm Outsourcing

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Annual survey shows strong growth for service providers and promises to continue into 2013.

CROs and CMOs Have Cause to Celebrate

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Jim Miller, president of PharmSource, examines the future direction of CROs/CMOs and the factors influencing the pharmaceutical contract services sectors.

A Look into the Future of Pharmaceutical Outsourcing: Perspectives from Jim Miller, president of PharmSource

Contract API manufacturers and fine-chemical producers roll out capacity and service expansions.

Inside INFORMEX: Evaluating the Market for Contract API Manufacturing

The evolving bio/pharmaceutical business model poses risk for CMOs.

CMOs Face a Kodak Moment

Expansion activity was limited as fine-chemical producers and CMOs of API and intermediates grapple with changing industry fundamentals.

Contract API Manufacturing: The Year in Review

In a quick-fire interview, Dr Stephen Taylor, Vice President & Commercial Director at Fujifilm Diosynth Biotechnologies, looks at some of the challenges facing biologics outsourcing.

Contract Manufacturing Services